OBJECTIVES: To constitute a registry on acromegaly, AcroBel, to evaluate the epidemiology and quality of care of acromegaly in Belgium and Luxembourg. DESIGN: A nationwide survey from June 2003 till September 2004 aiming to collect data from all patients with acromegaly who had visited the participating endocrine clinics after 1 January 2000. METHODS: Retrospective data collection coupled to a visit within the survey period, allowing sampling of metabolic parameters and centralised determination of GH and IGF-I. RESULTS: Four hundred and eighteen patients (51% men) were included, of which 96 were new cases, giving a mean incidence of 1.9 cases per million (c.p.m.) per year. The global prevalence was 41 c.p.m. but varied between 21 and 61 among different areas. Twenty-eight deaths were reported at a median age of 68 years in men and 74 years in women. The standardised mortality rate was significantly increased only in irradiated patients (2.70; confidence interval 1.60-4.55). Central measurements were available in 316 (75%) patients. Mean GH was < or = 2 microg/l in 65% and IGF-I was normal for age in 56%, while both criteria were fulfilled in 49%. Multimodal treatment was more effective than primary medical therapy, since 56.5% were controlled versus 24.3% (P < 0.0001). CONCLUSIONS: AcroBel provides an excellent tool to analyse the prevalence, incidence, treatment modalities and outcome of acromegaly in Belgium. This real-life survey reveals that only half of acromegalic patients received an adequate therapy resulting in cure or disease control when stringent biochemical criteria are used.
OBJECTIVES: To constitute a registry on acromegaly, AcroBel, to evaluate the epidemiology and quality of care of acromegaly in Belgium and Luxembourg. DESIGN: A nationwide survey from June 2003 till September 2004 aiming to collect data from all patients with acromegaly who had visited the participating endocrine clinics after 1 January 2000. METHODS: Retrospective data collection coupled to a visit within the survey period, allowing sampling of metabolic parameters and centralised determination of GH and IGF-I. RESULTS: Four hundred and eighteen patients (51% men) were included, of which 96 were new cases, giving a mean incidence of 1.9 cases per million (c.p.m.) per year. The global prevalence was 41 c.p.m. but varied between 21 and 61 among different areas. Twenty-eight deaths were reported at a median age of 68 years in men and 74 years in women. The standardised mortality rate was significantly increased only in irradiated patients (2.70; confidence interval 1.60-4.55). Central measurements were available in 316 (75%) patients. Mean GH was < or = 2 microg/l in 65% and IGF-I was normal for age in 56%, while both criteria were fulfilled in 49%. Multimodal treatment was more effective than primary medical therapy, since 56.5% were controlled versus 24.3% (P < 0.0001). CONCLUSIONS: AcroBel provides an excellent tool to analyse the prevalence, incidence, treatment modalities and outcome of acromegaly in Belgium. This real-life survey reveals that only half of acromegalicpatients received an adequate therapy resulting in cure or disease control when stringent biochemical criteria are used.
Authors: T Dusek; D Kastelan; A Melada; M Baretic; T Skoric Polovina; Z Perkovic; Z Giljevic; J Jelcic; J Paladino; I Aganovic; M Korsic Journal: J Endocrinol Invest Date: 2011-07-12 Impact factor: 4.256
Authors: Andrea Giustina; Philippe Chanson; David Kleinberg; Marcello D Bronstein; David R Clemmons; Anne Klibanski; Aart J van der Lely; Christian J Strasburger; Steven W Lamberts; Ken K Y Ho; Felipe F Casanueva; Shlomo Melmed Journal: Nat Rev Endocrinol Date: 2014-02-25 Impact factor: 43.330
Authors: Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli Journal: Endocrine Date: 2020-02-14 Impact factor: 3.633